2007: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's: Clinical Aspects and Therapeutics II
Search or Browse by Day

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's: Clinical Aspects and Therapeutics II

Sunday, November 11, 2007
2162
Development of a Provisional Core Set of Response Measures for Clinical Trials of Systemic Sclerosis
2163
A Multi-Center Placebo-Controlled “In-Life” Study of MQX-503 in Patients with Raynaud Phenomenon
2164
Defining Appropriate Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Delphi Consensus Study with Cluster Analysis
2165
MQX-503, A Novel Topical Nitroglycerin Formulation, Improves Severity of Raynaud Phenomenon in a Heterogeneous Patient Population
2166
Ambrisentan Therapy for Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases
2167
Addition of the Short Term Phosphodiesterase-5 Inhibitor Sildenafil to Iloprost Therapy for Scleroderma Digital Vasculopathy
See more of: ACR Abstract Submission ACR Concurrent Abstract Session
<< Previous Session Level | Next Session Level >>